Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3445147 | 0.76 | ALOX5 (0.39) | GRIA4ALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6329644 | 0.75 | ALOX5 (0.38) | GRIA4ALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6323246 | 0.72 | ALOX5 (0.39) | GRIA4ALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL27486779 | 0.68 | LMNA (0.41) | GRIA4ALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8354255 | 0.67 | CHRNB2 (0.38) | GRIA4ALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8605601 | 0.67 | ALOX5 (0.41) | GRIA4ALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22995905 | 0.67 | ALOX5 (0.39) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6323126 | 0.67 | ALOX5 (0.35) | GRIA4ALOX5CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8428133 | 0.66 | — | — | |
| SCHEMBL14928671 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | GRIA4 4468/4885ALOX5 650/4885GRIA2 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.